Company profile: Aurion Biotech
1.1 - Company Overview
Company description
- Provider of clinical-stage cell therapies to treat ocular diseases, developing a platform targeting leading forms of blindness. Based in Seattle, Boston and Tokyo, candidates include Vyznova, a cell therapy for corneal endothelial cell dystrophies using cultured cells from a single donor, and AURN001, a combination cell therapy for corneal edema involving intracameral injection of neltependocel and Y-27632.
Products and services
- AURN001: Combination-therapy cell product for treating corneal edema secondary to corneal endothelial dysfunction, administered via intracameral injection of neltependocel and Y-27632
- Vyznova: Single-donor–based cell therapy candidate for corneal endothelial cell dystrophies, using cultured cells from a single donor to treat multiple recipients
- Advanced Ocular Therapies Platform: Clinical-stage program that develops advanced therapies to treat ocular diseases, aiming to cure leading forms of blindness and transform the lives of millions of patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aurion Biotech
AgeX Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for age-related degenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AgeX Therapeutics company profile →
HemoGenyx Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of cell-based and antibody immunotherapies for blood diseases. Offerings include HEMO-CAR-T, a modified T-cell therapy for Acute Myeloid Leukemia (AML); CDX, a bispecific monoclonal antibody for relapsed/refractory AML and conditioning for bone marrow transplantation; and CBR, an immunotherapy platform to prevent and combat viral infections and certain cancers, with proof of concept for SARS-COV-2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoGenyx Pharmaceuticals company profile →
Trail Bio
HQ: United States
Website
- Description: Provider of human iPSC-derived cells and optimization technologies for drug discovery and cell therapies. Offers the HD-DoE Technology Platform, applying high-dimensional design-of-experiments to optimize cell growth and differentiation, and TrailBio Cells. Portfolio includes TrailBio Pre-Myelinating Oligodendrocytes Kit, Vascular Leptomeningeal Cells, and Insulin-Producing Islet-Like Clusters for screening and disease modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trail Bio company profile →
ArsenalBio
HQ: United States
Website
- Description: Provider of programmable CAR T-cell therapies for solid tumors, using synthetic biology to engineer T cells, including AB-1015 for ovarian cancer with dual antigen-sensing logic gating, AB-2100 for kidney cancer with potency enhancements, and the AB-3000 series for prostate cancer; collaborates with Bristol Myers Squibb and Genentech to advance next-generation T-cell therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArsenalBio company profile →
Coapt Systems
HQ: United States
Website
- Description: Provider of bio-absorbable implants for soft tissue fixation during facial cosmetic surgery, engaged in the design, development, manufacture, and marketing of these devices. Offerings include the ENDOTINE Forehead 3.0 bioabsorbable brow fixation device and ENDOTINE Forehead Instrument Kits comprising insertion tools, drill bits, and sterilization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coapt Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aurion Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aurion Biotech
2.2 - Growth funds investing in similar companies to Aurion Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aurion Biotech
4.2 - Public trading comparable groups for Aurion Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →